Hereditary angioedema plasma proteomics following specific plasma kallikrein inhibition with lanadelumab.

ABSTRACT:

Introduction

Plasma proteomics analyses were performed to identify novel disease state biomarkers of hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) and investigate the biological consequences of specific plasma kallikrein inhibition with lanadelumab.

Methods

Affinity proteomic analyses were performed using plasma from healthy controls (n=30) and patients with HAE-C1INH before (baseline, n=125) and after 6 months of treatment with lanadelumab (300 mg every 2 weeks, n=112) using the SomaScan platform.

Results

Relative plasma levels for several proteins differed significantly between controls and patients with HAE-C1INH, and between matched baseline and post-treatment samples from patients with HAE-C1INH. As expected, C1 inhibitor a

SUBMITTER: Sexton D 

PROVIDER: S-EPMC12098075 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature